PNC-29

1 study on PNC-29 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on PNC-29. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

PNC-29 studies and clinical research

2026-04-24 PubMed · in vitro · n preclinical

Anticancer peptide PNC-27 shows dose-dependent growth inhibition and cytotoxicity in primary human ovarian cancer cells.

These ex vivo findings suggest PNC-27 could be a valuable therapeutic agent for ovarian cancer, a disease with high mortality despite initial chemo-responsiveness. The peptide’s effectiveness against both newly diagno…

Research tools

Free, no account — handy when you're working with PNC-29.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$14 monthly or $88/year

Create an account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

PNC-29 studies and clinical research

Anticancer peptide PNC-27 shows dose-dependent growth inhibition and cytotoxicity in primary human ovarian cancer cells.

Research tools